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The kainic acid (kainate, KA) receptors belong to the class of ionotropic glutamate (iGlu) receptors in the 
central nervous system. Five subtypes have been identified, which have been termed KA1,2 and iGlu5–7. In 
the search for subtype selective ligands, α-amino-5-tert-butyl-3-hydroxy-4-isoxazolyl)propionic acid 
(ATPA), (4R)-methyl Glu (1a), and E-4-neopentylidene Glu (2f) have all previously been reported as 
selective agonists for the iGlu5 receptor subtype. In this paper, we present the pharmacological evaluation 
of a five-compound series of (4R)-alkyl Glu analogs (1b–e,g) which may be envisaged as 
conformationally released designs of ATPA and 4-alkylidenes 2a–h. Most notable is the pharmacological 
profile for (4R)-isopentyl Glu (1g) which shows a 10-fold increase in binding affinity for the iGlu5 
receptor subtype (Ki = 20.5 nM) in comparison with its E-4-alkylidene structural isomer 2g. Furthermore, 
1g displays high selectivity over other KA receptor subtypes (KA1,2 and iGlu6,7), AMPA-, and NMDA 
receptors (2050 and > 5000 fold, respectively). 
 




(S)-Glutamic acid (glutamate, Glu) is the major excitatory neurotransmitter in the central nervous system 
(CNS) activating the plethora of ionotropic Glu (iGlu) receptors and metabotropic Glu (mGlu) receptors 
([Bräuner-Osborne et al., 2000] and [Meldrum, 2000]). Whereas the iGlu receptors are ion channels and 
thus mediate a fast excitatory response (Na+, K+, Ca++ flux), the mGlu receptors are classified as G-
protein coupled receptors and generate a slower signal transduction through second messenger systems. 
On the basis of pharmacological studies, the iGlu receptors are further divided into: 2-amino-3-(3-
hydroxy-5-methyl-4-isoxazolyl)propionic acid (AMPA) receptors (homo- or heteromeric receptors 
comprising the subunits iGlu1–4), kainic acid (KA) receptors (homo- or heteromeric receptors comprising 
the subunits iGlu5–7 and KA1,2) (Wisden and Seeburg, 1993), and the N-methyl-d-aspartic acid (NMDA) 
receptors (heteromeric receptors comprising the subunits NR1, NR2A–D, NR3A–C). The mGlu receptors 
comprise eight homodimeric subtypes, mGlu1–8, which are grouped with respect to the second messenger 
system activated, pharmacology, and molecular biology (group I: mGlu1,5 receptors; group II: mGlu2,3 
receptors; group III: mGlu4,6–8 receptors) (Ferraguti and Shigemoto, 2006). Termination of the excitatory 
signal is controlled by uptake of Glu from the synaptic cleft by the excitatory amino acid transporters 
(EAATs) (Beart and O'Shea, 2007). To date, five subtypes have been identified of which EAAT1–3 are 
high capacity Glu transporting proteins, EAAT4 functions predominantly as a chloride ion channel and 
EAAT5 is present exclusively in the retina.  
In order to study the function of a single receptor subtype, when found in its intrinsic biological 
environment, the application of subtype selective ligands (agonists, partial agonists or antagonists) is a 
useful pharmacological approach. In 1997 the AMPA-analog, α-amino-5-tert-butyl-3-hydroxy-4-
isoxazolyl)propionic acid (ATPA), was shown to be a highly selective ligand for the iGlu5 receptor 
subtype. Concurrently (4R)-methyl Glu (1a) was found to display preference for KA receptors over 
AMPA, NMDA, and the mGlu receptors ([BraunerOsborne et al., 1997], [Gu et al., 1995], [Sagot et al., 
2008] and [Zhou et al., 1997]), and in 2001 we reported that E-4-neopentylidene Glu (2f) (Bunch et al., 
2001) is a highly selective iGlu5 receptor ligand (Table 1). In this paper we present the pharmacological 
investigation of a five-compound series of (4R)-alkyl Glu analogs (1b–e,g) which may be viewed as 
conformationally released analogs of 2b–e,g. Such a distinct – yet confined – change in physical 
chemical property is interesting as it allows for a detailed investigation of ligand flexibility as opposed to 
receptor subtype selectivity. 
Table 1.  
Binding affinities of (4R)-alkyl Glu analogs (1a–e,g), E-4-alkylidene Glu analogs (2a–h), AMPA, ATPA, 
and KA at native iGlu receptors (rat brain synaptosomes) and at cloned rat homomeric iGlu5–7 receptor 
subtypes. 
 
a KA1,2 are the predominant KA receptor subtypes expressed in native rat synaptosomes. 
b Data taken from original papers: 1a, ([BraunerOsborne et al., 1997], [Gu et al., 1995], [Sagot et al., 2008] and [Zhou et al., 
1997]); 2a, ([Baker et al., 2000] and [BraunerOsborne et al., 1997]); 2b–e,g, (Baker et al., 2000); 2f,h, (Bunch et al., 2001); 
AMPA, ([Clarke et al., 1997] and [Vogensen et al., 2000]); ATPA, ([Clarke et al., 1997] and [Stensbol et al., 1999]); KA, 
([Baker et al., 2000], [Conti et al., 1999] and [Sagot et al., 2008]).  
 
2. Materials and methods 
2.1. Binding affinities at native and homomeric ionotropic Glu receptors 
 
Binding affinities for 1b–e,g at native AMPA, KA, NMDA receptors (rat synaptosomes) were determined 
according to the previously published experimental procedure (Hermit et al., 2004) using radioligands 
[3H]AMPA, [3H]KA (representing predominantly subtypes KA1,2), and [3H]CGP39653, respectively. 
Determination of binding affinities for 1b–e,g and 2f,h at cloned rat homomeric receptor subtypes iGlu5–7 
were carried out following the procedure described earlier, using [3H]-SYM2081 as the radioligand 
(Sagot et al., 2008). 
 
2.2. Molecular modelling 
 
The modeling study was performed using the software package MOE (Molecular Operating Environment, 
v2004.03, Chemical Computing Group, 2004) using the build-in mmff94x forcefield and the GB/SA 
continuum solvent model. Compound 1g was submitted to a stochastic conformational search and with 
respect to its global minimum returned (∆G in kcal/mol), conformations above + 7 kcal/mol were 
discarded. The γ-carboxylate group was protonated prior to execution of the conformational search, as 
this gave a larger and thus more reliable number of output conformations. Superimpositions of ligands, 
were carried out using the built-in function in MOE, by fitting the ammonium group and the two 
carboxylate groups. The conformation of ATPA was adapted from X-ray structure when bound in the 
iGlu2 subunit (PDB: 1 nnk). 
 
3. Results 
3.1. Binding affinities at native Glu receptor subtypes 
 
In binding assays at native AMPA, KA and NMDA receptors, 1b shows preference for the KA receptors 
with decreasing affinity as the 4-substituent is enlarged in size and bulk (1a–e,g). Eventually, compound 
1g displays very low affinity for any of the three iGlu receptor subgroups (42, > 100, > 100 µM, 
respectively, Table 1). 
 
3.2. Binding affinities at cloned homomeric Glu receptor subtypes 
 
At cloned homomeric iGlu5–7 receptor subtypes, Glu analog 1b displayed a 35- and 10-fold preference for 
iGlu5 over subtypes iGlu6,7, respectively. As the 4R-alkyl substituent is increased in length and bulkiness, 
this trend is strengthened (Table 1 and Fig. 1), and eventually Glu analog 1g is highly selective for iGlu5 
receptor subtype (Ki = 20.5 nM), displaying more than 5000-fold and 300-fold selectivity over iGlu6,7 
receptor subtype, respectively (Table 2). 
 
Fig. 1. Binding affinities (pKi [nM]) of (4R)-alkyl Glu analogs 1a–e,g (top) and E-4-alkylidene Glu 
analogs 2a–h (bottom) at cloned homomeric iGlu5–7 receptor subtypes. 
Table 2.  
Receptor subtype selectivity calculated and normalized from data presented in Table 1 (iGlu5 receptor 
subtype set to 1). 
 AMPA KA1,2a NMDA iGlu5 iGlu6 iGlu7 
1g 2050 > 5000 > 5000 1 > 5000 300 
2f 80 > 4200 > 4200 1 > 4200 90 
2g – – – 1 2830 – 
ATPA 450 5750 > 25,000 1 > 25,000 2500 
a Predominant KA receptor subtypes expressed in native rat synaptosomes.  
4. Discussion 
 
Despite the fact that Glu is a highly flexible molecule (Fig. 2), it has been shown in several X-ray 
crystallographic and medicinal chemistry studies, that Glu agonizes iGlu receptors in a well-defined 
conformation termed the folded conformation ([Bunch and Krogsgaard-Larsen, 2009], [Bunch et al., 
2003] and [Hogner et al., 2002]). On the other hand, when activating the mGlu receptors, Glu adopts an 
extended conformation ([Hayashi et al., 1992] and [Kozikowski et al., 1998]). 
 
 
Fig. 2. Rotation of the C(2)–C(3) and C(3)–C(4) bonds allows Glu to adapt nine different staggered 
conformations. Of these, the two low-energy conformations are termed the Glu folded and extended 
conformations. These two Glu conformations are also observed when Glu is crystallized with iGlu 
receptor subunits (e.g. the iGlu5 subunit: PDB code: 1TXF) and mGlu1 subunit (PDB code: 1EWK). 
 
Recently we reported the synthesis and pharmacological evaluation of a series of (4R)-alkyl Glu analogs 
at EAAT1–3 (Alaux et al., 2005). In extension from earlier findings, we showed that introduction of a large 
variety of longer and more bulky (4R)-alkyl substituents also endorses the folded conformation as the 
global low-energy conformation of Glu. In comparison, this low-energy conformational preference is also 
preferred for E-4-alkylidene Glu analogs 2a–h, AMPA, and ATPA (Fig. 3). Furthermore, a general 
feature for all of these Glu analogs, is the observed increase in preference for the iGlu5 receptor subtype, 
as the alkyl group is extended in length and bulk (1a → 1g, 2a → 2f and AMPA → ATPA; Table 1). This 
observation may be explained by comparing the size of the iGlu receptor binding pockets: For subunit 
iGlu5 it has been estimated to be approximately 20% larger as compared to subunit iGlu6 and 




Fig. 3. Superimposition of low-energy conformations of 1g (∆∆G = 0 to + 1 kcal/mol) (type code/green) 
and ATPA (purple). The conformation of 1g shown in green resembles the conformation of ATPA best. 
(For interpretation of the references to colour in this figure legend, the reader is referred to the web 
version of this article.) 
 
(4R)-Alkyl Glu analogs 1a–e,g are conformationally released structural analogs of 4-alkylidenes 2a–h. 
This confined modification of physical chemical property may allow for a detailed investigation of ligand 
flexibility opposed to receptor subtype selectivity. Comparing the binding affinity profiles of series 1 and 
2 at iGlu5–7 receptor subtypes reveals that both series display increasing selectivity as well as binding 
affinity for iGlu5, as the 4-substituents is extended in length and bulk. However, from this resemblance 
two divergences are noted: Firstly, 1g vs. 2g displays a 10-fold difference in binding affinity at the iGlu5 
receptor subtype (Ki = 20.5 and 224 nM, respectively). This finding is intriguing and raises the question 
as to what origin this observation has. One explanation could be that the more flexible ligand, 1g, may 
allow for a more tight domain closure, favoring both ligand–receptor and receptor–receptor interactions. 
A different explanation could be enhanced hydrophobic interactions with the receptor protein. Secondly, 
2d stands out from the trend, displaying significantly lower binding affinity to the iGlu5 receptor subtype 
as compared to 2c and 2e, as well as 1c–e. However, this is explained on the basis that 2d is structurally 
quite distinct from preceding analogs 2a–c and subsequent analogs 2e–f, as it has a methyl group in the Z-
1′ position as opposed to hydrogen. 
In conclusion, Glu analogs 1b–e,g are a conformationally released structural design of 2a–h and ATPA. 
Most notably, 1g displays high affinity for the KA receptor subtype iGlu5 with a high degree of selectivity 
over receptor subtypes iGlu6,7 (fold ratio: > 5000, 300, respectively), KA subtypes KA1/KA2 (fold ratio: 
> 5000, determined by KA binding at native rat synaptosomes), AMPA receptors (2050 fold, determined 
by AMPA binding at native rat synaptosomes), and NMDA receptors (> 5000 fold, determined by 
CGP39653 binding at native rat synaptosomes), making 1g a valuable pharmacological tool. Furthermore, 
1g displays an intriguing 10-fold higher binding affinity at iGlu5 receptor subtype than its corresponding 
E-4-alkylidene isomer 2g. This observation encourages an expansion of the (4R)-alkyl Glu series by the 
synthesis of corresponding saturated analogs of 2f,h, and a following investigation whether such 
difference in binding affinity at iGlu5 receptor subtype is a generally observable fact and ultimately if it 
translates into functional differences. 
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